192
Participants
Start Date
August 12, 2025
Primary Completion Date
July 23, 2027
Study Completion Date
December 29, 2028
Rilzabrutinib
Pharmaceutical form:Tablet -Route of administration:Oral
Placebo
Pharmaceutical form:Tablet -Route of administration:Oral
RECRUITING
Investigational Site Number : 0560003, Brussels
RECRUITING
Investigational Site Number : 0560002, Brussels
RECRUITING
Richmond University Medical Center- Site Number : 8400038, Staten Island
RECRUITING
Investigational Site Number : 3000003, Athens
RECRUITING
Investigational Site Number : 3760002, Afula
RECRUITING
Investigational Site Number : 3800004, Milan
RECRUITING
Investigational Site Number : 7240002, Madrid / Madrid
RECRUITING
Investigational Site Number : 7240001, Madrid
ACTIVE_NOT_RECRUITING
Bioresearch Partners- Site Number : 8400005, Hialeah
RECRUITING
Investigational Site Number : 7920003, Mersin
RECRUITING
Investigational Site Number : 2500002, Créteil
RECRUITING
Investigational Site Number : 3760005, Haifa
RECRUITING
Investigational Site Number : 3760006, Haifa
RECRUITING
Hospital Santa Izabel / Santa Casa de Misericordia da Bahia- Site Number : 0760006, Salvador
RECRUITING
Universidade Federal da Bahia - Site Number : 0760009, Salvador
RECRUITING
EBSERH Hospital das Clínicas da Universidade Federal de Goiás- Site Number : 0760002, Goiânia
RECRUITING
Fund. Faculdade Reg de Medicina de SJRP- Site Number : 0760001, São José do Rio Preto
RECRUITING
Hospital Samaritano- Site Number : 0760005, São Paulo
RECRUITING
Investigational Site Number : 7920001, Adana
RECRUITING
Investigational Site Number : 7920002, Balcali Adana
RECRUITING
Investigational Site Number : 8260002, London
RECRUITING
Investigational Site Number : 8260001, London
Lead Sponsor
Sanofi
INDUSTRY